| Title |
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
|
|---|---|
| Published in |
Journal of Neuro-Oncology, September 2010
|
| DOI | 10.1007/s11060-010-0389-0 |
| Pubmed ID | |
| Authors |
Klaus Maier-Hauff, Frank Ulrich, Dirk Nestler, Hendrik Niehoff, Peter Wust, Burghard Thiesen, Helmut Orawa, Volker Budach, Andreas Jordan |
| Abstract |
Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan-Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6-16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (P < 0.01). No other variables predicting longer survival could be determined. The side effects of the new therapeutic approach were moderate, and no serious complications were observed. Thermotherapy using magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and leads to longer OS-2 compared to conventional therapies in the treatment of recurrent glioblastoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 920 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | <1% |
| Spain | 3 | <1% |
| United Kingdom | 3 | <1% |
| Brazil | 2 | <1% |
| Egypt | 2 | <1% |
| Germany | 2 | <1% |
| Italy | 2 | <1% |
| Japan | 2 | <1% |
| Russia | 2 | <1% |
| Other | 7 | <1% |
| Unknown | 890 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 189 | 21% |
| Researcher | 145 | 16% |
| Student > Master | 131 | 14% |
| Student > Bachelor | 86 | 9% |
| Student > Doctoral Student | 49 | 5% |
| Other | 118 | 13% |
| Unknown | 202 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 103 | 11% |
| Medicine and Dentistry | 93 | 10% |
| Biochemistry, Genetics and Molecular Biology | 79 | 9% |
| Engineering | 78 | 8% |
| Physics and Astronomy | 78 | 8% |
| Other | 245 | 27% |
| Unknown | 244 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#1,128,699
of 25,837,817 outputs
Outputs from Journal of Neuro-Oncology
#39
of 3,329 outputs
Outputs of similar age
#3,199
of 102,776 outputs
Outputs of similar age from Journal of Neuro-Oncology
#1
of 25 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,329 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 102,776 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.